Soni Medicare (BOM:539378) Research & Development: ₹0.0 Mil (TTM As of Mar. 2026)


BOM:539378 Soni Medicare Ltd BOM:539378
48 GF Score
Price ₹70.20
GF Value ₹30.55
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Soni Medicare Research & Development?

Soni Medicare BOM:539378 48 Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus rates BOM:539378 with a GF Score™ of 48/100 and a GF Value™ of ₹30.55 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Soni Medicare's Research & Development for the three months ended in Mar. 2026 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.

Soni Medicare  (BOM:539378) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Soni Medicare Research & Development Related Terms

Soni Medicare Research & Development Historical Data

* Premium members only.

The historical data trend for Soni Medicare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Soni Medicare Research & Development Chart

Soni Medicare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Soni Medicare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:539378
48GF Score
Soni Medicare Ltd BOM:539378
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Soni Medicare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Soni Medicare (BOM:539378) has a Research & Development of ₹0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Soni Medicare and its competitors.
Is Soni Medicare's Research & Development too high?
Soni Medicare's current Research & Development is ₹0.0 Mil. Overall, Soni Medicare has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Soni Medicare's Research & Development compare to HCA and THC?
Soni Medicare's Research & Development of ₹0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Soni Medicare and its competitors. Soni Medicare's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soni Medicare stock overvalued right now?
Based on GuruFocus' analysis, Soni Medicare (BOM:539378) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹30.55, compared to a current price of ₹70.20 — trading 129.8% above its estimated fair value. The current Research & Development is ₹0.0 Mil. Soni Medicare's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Soni Medicare (BOM:539378), the current Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Soni Medicare (BOM:539378) Overvalued in 2026?

Based on GuruFocus' analysis, Soni Medicare stock appears to be overvalued. The current stock price of ₹70.20 is trading 129.8% above its estimated GF Value™ of ₹30.55. GuruFocus considers Soni Medicare to be Significantly Overvalued.

Key valuation signals for BOM:539378:

  • Research & Development: ₹0.0 Mil
  • GF Value™: ₹30.55 vs. price of ₹70.20 (129.8% above fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the BOM:539378 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Soni Medicare Business Description

Address Jawaharlal Nehru Marg, 38, Kanota Bagh, Jaipur, RJ, IND, 302004
Soni Medicare Ltd is an India-based company engaged in providing human health services. It provides services like education and courses, health check-ups, patient counseling, outpatient services, inpatient services, emergency care, intensive care unit, dialysis centers, operation theatre, laboratory services, physiotherapy, blood bank, oncology, pharmacies, radiology services, and orthopedic services. The company generates its revenue from providing super specialty and general hospital services.
48GF Score

Get the complete analysis for BOM:539378

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹70.20
Price
₹30.55
GF Value